Sept. 11 – The Stevanato Group, headquartered in Piombino Dese (PD), is an international leader in the manufacture of insulin vials and glass containers for pharmaceutical use. The company also produces the technology necessary for the glass containers’ production and transformation. Stevanato recently released its data for the first semester of 2014, which ended on June 30, and the Group boasts a consolidated turnover of €134.1 million, for a 22.2% increase compared to the €109.7 million of the first semester of 2013. In the first half of 2014, Stevanato recorded significant increases in the main business areas in which it operates: the Pharmaceutical Systems Division and the Engineering Systems Division. The pharmaceutical division contributed 87% to its consolidated revenues, while the remaining 13% was achieved by the Engineering Division. “We are very satisfied with the way this first semester went, because we our growth is well distributed in all markets and business areas in which we operate,” said Franco Stevanato, CEO of the Group. The company’s geographic expansion on a global level allows the Groups “to be closer to the customer – as explains a note – The Stevanato Group is opening new trade offices and new production sites in the countries where it exports more.” “Our two main achievements in this sense so far are our production plant Zhangjiagang in China, which opened last June, and the production site in Monterrey, Mexico – adds Marco Stevanato, vice president and internationalization project manager of the group – which is already working at full capacity. The plant in China will be fully operational by the end of next year, after which we have already provided for a further production expansion in Asia Pacific. We are already planning to increase our presence through the creation of new production sites in other areas and we are currently carrying out a scouting activities in the Brazilian market.”
